MedImmune, Dr. Lutz Jermutus
Hollfelder group, Department of Biochemistry, University of Cambridge
Contact email: firstname.lastname@example.org
ES-Cat start date: October 2017
I studied chemical engineering at the “Ecole Nationale Supérieure de Chimie de Montpellier” (ENSCM), in France and received my BSc in 2014. During my studies I worked on the oxidation and reduction reactions coupled with platinum complexes in the “Institut des sciences moléculaires” of Marseille (ISM2). During my Master degree I spent 6 month in Wales, Cardiff and had the opportunity to work in the group of Yuhsuan Tsai on the synthesis of different fluorophores for bioorthogonal labelling of O-GlcNAc modification. I had the opportunity to learn some molecular biology tools. After this experience I worked for 3 months in a start-up: Phost’in which develops first-in-class anti-cancer synthetic compounds unblocking immune response and down modulating invasiveness for the treatment of agressive solid tumors. For my master degree I decided to major in follow a double-degree in Chemistry and Biology with the “Université des sciences de Montpellier” and the ENSCM. In course of my master’s thesis I worked on the modulation of therapeutic protein quality by cell culture design at Merck Biopharma under the supervision of David Brühlmann.
Training and Transferable Skills:
- Analytical Chemistry (high performance liquid chromatography, gas chromatography,
- Mass spectrometry, NMR (31P, 1H, 13C, COSY)
- Biochemistry (enzymology, protein purification and characterization)
- Cloning (PCR, electrophoresis, generation of libraries)
- Cell culture (Mammalian and bacterial)
I am doing a PhD in collaboration between the Hollfelder group at the University of Cambridge and Medimmune. The general topic of my project concerns the development of new antibody therapies using the advantages of proteases in order to lead to novel biologics modalities. More specifically, my project is focused on kidney and heart diseases which are more and more prevalent in our societies. My aim is to find a potential platform that would help to find leads that would pass with fewer troubles the clinical stages by avoiding unintended secondary effects.